收藏切换
Mining and analysis of irinotecan and fluorouracil safety signals based on FDA adverse event database
收藏切换
Xianglei WU1, 2, Chendong QI1, Shengying GU1, Shuowen WANG1, *, Guorong FAN1
World Clinical Drug | 2023, 44(3) : 268 - 274
Less
收藏切换
World Clinical Drug | 2023, 44(3): 268-274
• Article •
Mining and analysis of irinotecan and fluorouracil safety signals based on FDA adverse event database
Full
Xianglei WU1, 2, Chendong QI1, Shengying GU1, Shuowen WANG1, *, Guorong FAN1
Affiliations
  • 1.Department of Clinical Pharmacy, Shanghai Jiao Tong University Affiliated Shanghai General Hospital, Shanghai 200080, China
  • 2.Department of Pharmacy, the Third Hospital Affiliated to Naval Medical University, Shanghai 200438, China
Published: 2023-03-10 doi: 10.13683/j.wph.2023.03.012
Outline
收藏切换
Objective

To explore and analyze the safety signals of irinotecan and fluorouracil.

Methods

The adverse drug reaction (ADR) reports with irinotecan and fluorouracil as suspects included in the FDA adverse event reporting system (FAERS) from January 2004 to September 2021 were selected. The ADR signals were detected by reporting odds ratio and proportional reporting signals.

Results

For the primary screening, 583, 1 239 and 674 preferred term (PT) were obtained by irinotecan, fluorouracil and the combination of two drugs, respectively. The top 3 PT in the number of reports of the combination of two drugs were diarrhea (5.88%), neutropenia (3.41%) and nausea (3.26%), respectively. After secondary screening, 28, 70 and 60 PT were obtained by irinotecan, fluorouracil and the combination of two drugs, and 10, 17 and 13 system organ class were involved, respectively. In the double-screened PT cholinergic syndrome, the reporting odds ratio was 127.4 and 95% confidence interval was (82.9, 195.6). By comparing the Venn diagram of primary screening and secondary screening, the overlap of PT with prominent signal was significantly reduced among irinotecan, fluorouracil and the combination of two drugs.

Conclusion

When using single drug, ADR is more prominent.

adverse event  /  irinotecan  /  fluorouracil  /  signal mining
吴相雷, 戚晨冬, 顾圣莹, 汪硕闻, 范国荣. 基于FDA不良事件数据库对伊立替康和氟尿嘧啶安全信号的挖掘与分析. 世界临床药物, 2023 , 44 (3) : 268 -274 . DOI: 10.13683/j.wph.2023.03.012
Xianglei WU, Chendong QI, Shengying GU, Shuowen WANG, Guorong FAN. Mining and analysis of irinotecan and fluorouracil safety signals based on FDA adverse event database[J]. World Clinical Drug, 2023 , 44 (3) : 268 -274 . DOI: 10.13683/j.wph.2023.03.012
Year 2023 volume 44 Issue 3
6
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.03.012
  • Receive Date:2022-07-19
  • Online Date:2026-11-18
  • Published:2023-03-10
Article Data
Affiliations
History
  • Received:2022-07-19
Funding
Affiliations
    1.Department of Clinical Pharmacy, Shanghai Jiao Tong University Affiliated Shanghai General Hospital, Shanghai 200080, China
    2.Department of Pharmacy, the Third Hospital Affiliated to Naval Medical University, Shanghai 200438, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.03.012
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT